ArticleJCO precision oncology2019

Prioritization of Therapy Options for a Patient With High Tumor Mutation Burden and Microsatellite Instability but No Clinical Benefit From Immunotherapy.

Ryan S Nelson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.